Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a controlled clinical trial.

The route of administration until now had been intranasal, but because the tablets were introduced for the treatment of diabetes insipidus they have also become available for the treatment of PNE.

Who Took Part

The study group was 25 adolescents.

PubMed indexes the participants as teenagers, both men and women.

How the Study Was Run

The design is described as double-blind, single-blind, placebo-controlled and crossover.

Neither the adolescents nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

In this single-blind Vasopressin study one party knew the assignments and the other did not.

Some adolescents received a placebo instead of Vasopressin, giving a reference point.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Deamino Arginine Vasopressin, Enuresis, Remission Induction and Tablets.

What This Means in Plain Language

The paper is a double-blind, single-blind and placebo-controlled study of Vasopressin and Desmopressin in 25 adolescents.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (Pediatrics), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.